CPT code 82234 denotes a laboratory chemistry test quantifying beta–amyloid 42, a biomarker relevant to Alzheimer’s disease evaluation. As biomarker testing expands in clinical neurology and research settings, reliable coding for specialized assays like beta–amyloid 42 supports appropriate billing, claims adjudication, and broader surveillance of diagnostic utilization across the country. Payers addressed in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

This article provides a concise overview of CPT code 82234, explaining the clinical context of beta–amyloid 42 testing, the typical laboratory service setting, and why accurate coding matters for clinical workflows and payer processing. Readers will find benchmarks for payer coverage where available, a summary of common billing modifiers, and notes on clinical relevance to Alzheimer’s disease diagnosis and management. Where input data is unavailable, the publication explicitly notes those gaps. The piece is written for a national audience of billing professionals, laboratory directors, and policy analysts seeking a clear, practical reference on coding and clinical context for beta–amyloid 42 assays.